TAXOL

LOE Approaching

paclitaxel

NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT07433673Phase 2Recruiting

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Started Aug 2026
20 enrolled
Colon and Rectal Cancer
NCT07362186Phase 3Not Yet Recruiting

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Started Apr 2026
400 enrolled
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
NCT07445295Phase 3Not Yet Recruiting

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Started Mar 2026
NCT07488884Phase 1Not Yet Recruiting

Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Started Mar 2026
30 enrolled
Pancreatic Cancer ResectablePancreatic Cancer
NCT07290140N/ANot Yet Recruiting

Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis

Started Mar 2026
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.